Non-small-cell lung cancer
Conditions
Interventions
Proton radiotherpay with a higher radiation dose to the primary lung tumour 
(radiotherapy dose escalation).
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Age >=18 years - WHO performance score 0-2 - Histologically proven stage III NSCLC - Planned for CCRT and adjuvant immunotherapy (intention to treat) - Primary tumour volume outside of mediastinal PRV (i.e., mediastinal envelope + 5 mm) >=60% of total primary tumour volume (true for 75% of patients in preliminary analysis), for sufficient dose escalation -Signed informed consent to participate in the Standard Follow-up Program Lung -Signed informed consent for this trial prior to registration/randomization
Exclusion criteria
Exclusion criteria: - Chemotherapy not given concurrently with radiotherapy - Upfront decision that patient does not qualify for adjuvant immunotherapy - Primary tumor overlapping at with more than 40% of the mediastinal planning risk volume - Unable or unwilling to understand the information on trial-related topics, to give informed consent or to fill out quality of life questionnaires
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severe (grade 3+) adverse effects in the first year after radiotherapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| -Local control of the lung tumour -Progresion-free survival -Distant metastasis control -Overall survival -Grade 2+ adverse effects (i.e., requiring medication), both acute and late -Qualifying for adjuvant immunotherapy after finishing chemoradiotherapy yes/no -Quality of life -Lymphocyte counts after finishing chemoradiotherapy | — |
Countries
Netherlands
Contacts
Public ContactA.C. Hessels
Universitair Medisch Centrum Groningen
Outcome results
None listed